Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 455

1.

Managing Lung Cancer with Comorbid Interstitial Pneumonia.

Ichihara E, Miyahara N, Maeda Y, Kiura K.

Intern Med. 2019 Sep 18. doi: 10.2169/internalmedicine.3481-19. [Epub ahead of print]

2.

EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice.

Higo H, Ohashi K, Makimoto G, Nishii K, Kudo K, Kayatani H, Watanabe H, Kano H, Ninomiya K, Hotta K, Maeda Y, Kiura K.

Lung Cancer. 2019 Oct;136:86-93. doi: 10.1016/j.lungcan.2019.08.019. Epub 2019 Aug 20.

PMID:
31470227
3.

Solitary pulmonary nodules caused by Mycobacterium avium complex.

Marukawa M, Taniguchi A, Kimura G, Kunichika N, Kuyama S, Maeda Y, Kiura K, Miyahara N; OKAYAMA Respiratory Disease Study Group (ORDSG).

Respir Investig. 2019 Aug 8. pii: S2212-5345(19)30048-6. doi: 10.1016/j.resinv.2019.07.001. [Epub ahead of print]

PMID:
31402330
4.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS.

Respir Investig. 2019 Jul 31. pii: S2212-5345(18)30312-5. doi: 10.1016/j.resinv.2019.06.001. [Epub ahead of print] Review.

PMID:
31377122
5.

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.

Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K.

J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602-1. doi: 10.1016/j.jtho.2019.07.017. [Epub ahead of print]

PMID:
31374369
6.

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.

Nakasuka T, Ichihara E, Makimoto G, Maeda Y, Kiura K.

J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009. No abstract available.

PMID:
31345339
7.

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.

Watanabe H, Ohashi K, Nishii K, Seike K, Makimoto G, Hotta K, Maeda Y, Kiura K.

Intern Med. 2019 Oct 15;58(20):3033-3037. doi: 10.2169/internalmedicine.2875-19. Epub 2019 Jul 10.

8.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

9.

Successful Treatment of Metastatic Urothelial Carcinoma after Accurate Diagnosis by Immunohistochemistry.

Makimoto G, Nishimori H, Kondo R, Yanai H, Sugimoto M, Oda N, Kubo T, Hotta K, Tabata M, Kiura K, Maeda Y.

Acta Med Okayama. 2019 Jun;73(3):279-284. doi: 10.18926/AMO/56873.

10.

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.

Iwamoto Y, Ichihara E, Hara N, Nakasuka T, Ando C, Umeno T, Hirabae A, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 Jun 12. pii: hyz086. doi: 10.1093/jjco/hyz086. [Epub ahead of print]

PMID:
31187861
11.

Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.

Nishii K, Hotta K, Ninomiya K, Kato Y, Ichihara E, Ohashi K, Ninomiya T, Kubo T, Rai K, Tabata M, Maeda Y, Kiura K.

Respir Investig. 2019 Sep;57(5):460-465. doi: 10.1016/j.resinv.2019.04.004. Epub 2019 Jun 8.

PMID:
31186170
12.

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.

Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K.

Lung Cancer. 2019 Jun;132:54-58. doi: 10.1016/j.lungcan.2019.02.021. Epub 2019 Apr 6.

PMID:
31097094
13.

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 May 15. pii: hyz066. doi: 10.1093/jjco/hyz066. [Epub ahead of print]

PMID:
31090906
14.

Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation.

Higo H, Miyahara N, Taniguchi A, Maeda Y, Kiura K.

Respir Investig. 2019 Jul;57(4):321-324. doi: 10.1016/j.resinv.2019.04.003. Epub 2019 May 9. Review.

PMID:
31080050
15.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6.

PMID:
31072612
16.

Recent trends in the treatment of unresectable stage III non-small-cell lung cancer.

Makimoto G, Hotta K, Kiura K.

Respir Investig. 2019 Jul;57(4):330-336. doi: 10.1016/j.resinv.2019.03.004. Epub 2019 Apr 15. Review.

PMID:
31000495
17.

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K.

Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1.

PMID:
30938103
18.

Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.

Senoo S, Ninomiya K, Hotta K, Kiura K.

Int J Clin Oncol. 2019 May;24(5):461-467. doi: 10.1007/s10147-019-01424-y. Epub 2019 Mar 7. Review.

PMID:
30847617
19.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

20.

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities.

Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, Ninomiya T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Takigawa N, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 May 1;49(5):458-464. doi: 10.1093/jjco/hyz016.

PMID:
30793176
21.

Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy.

Suzawa K, Soh J, Takahashi Y, Sato H, Shien K, Yamamoto H, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

Surg Today. 2019 Jul;49(7):601-609. doi: 10.1007/s00595-019-1774-8. Epub 2019 Feb 8.

PMID:
30734881
22.

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib.

Makimoto G, Ohashi K, Senoo S, Hotta K, Maeda Y, Kiura K.

Intern Med. 2019 Jun 1;58(11):1625-1627. doi: 10.2169/internalmedicine.2152-18. Epub 2019 Feb 1.

23.

A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation.

Morichika D, Miyahara N, Fujii U, Taniguchi A, Oda N, Senoo S, Kataoka M, Tanimoto M, Kakuta H, Kiura K, Maeda Y, Kanehiro A.

Respir Res. 2019 Jan 3;20(1):2. doi: 10.1186/s12931-018-0963-0.

24.

Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation.

Oda N, Miyahara N, Taniguchi A, Morichika D, Senoo S, Fujii U, Itano J, Gion Y, Kiura K, Kanehiro A, Maeda Y.

Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L407-L417. doi: 10.1152/ajplung.00386.2018. Epub 2019 Jan 3.

PMID:
30604629
25.

Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival.

Tanaka S, Miyoshi K, Higo H, Kurosaki T, Otani S, Sugimoto S, Yamane M, Kiura K, Toyooka S, Oto T.

Respir Investig. 2019 Mar;57(2):165-171. doi: 10.1016/j.resinv.2018.12.002. Epub 2018 Dec 30.

PMID:
30600175
26.

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.

Senoo S, Ninomiya T, Makimoto G, Nishii K, Kano H, Watanabe H, Hata Y, Kubo T, Tanaka T, Hotta K, Maeda Y, Kiura K.

Intern Med. 2019 Apr 1;58(7):985-989. doi: 10.2169/internalmedicine.0890-18. Epub 2018 Dec 18.

27.

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.

Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K.

Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1.

PMID:
30514667
28.

Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer.

Ogata T, Katsui K, Yoshio K, Ihara H, Katayama N, Soh J, Kuroda M, Kiura K, Maeda Y, Toyooka S, Kanazawa S.

Acta Med Okayama. 2018 Oct;72(5):507-513. doi: 10.18926/AMO/56249.

29.

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.

Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.

Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1.

PMID:
30276451
30.

Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.

Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K.

Clin Lung Cancer. 2018 Nov;19(6):e861-e864. doi: 10.1016/j.cllc.2018.07.010. Epub 2018 Aug 9.

PMID:
30172698
31.

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.

Hotta K, Ninomiya K, Ichihara E, Kiura K.

Int J Clin Oncol. 2019 Jan;24(1):41-45. doi: 10.1007/s10147-018-1344-x. Epub 2018 Aug 29. Review.

PMID:
30159691
32.

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.

Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11.

33.

Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M.

Senoo S, Ohashi K, Nishii K, Hara N, Kano H, Ninomiya K, Maeda Y, Kiura K.

J Thorac Oncol. 2018 Aug;13(8):e140-e142. doi: 10.1016/j.jtho.2018.03.016. No abstract available.

34.

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer.

Ichihara E, Hotta K, Kubo T, Higashionna T, Ninomiya K, Ohashi K, Tabata M, Maeda Y, Kiura K.

Oncotarget. 2018 Jun 29;9(50):29525-29531. doi: 10.18632/oncotarget.25705. eCollection 2018 Jun 29.

35.

Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.

Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K.

Cancer Sci. 2018 Sep;109(9):2852-2862. doi: 10.1111/cas.13724. Epub 2018 Aug 9.

36.

Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.

Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K.

Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080.

37.

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K.

Cancer Sci. 2018 Aug;109(8):2532-2538. doi: 10.1111/cas.13651. Epub 2018 Jun 29.

38.

Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation.

Minami D, Takigawa N, Oki M, Saka H, Shibayama T, Kiura K.

Respir Investig. 2018 Jul;56(4):356-360. doi: 10.1016/j.resinv.2018.03.006. Epub 2018 May 10.

PMID:
29764751
39.

Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?

Sato H, Soh J, Hotta K, Katsui K, Kanazawa S, Kiura K, Toyooka S.

Ann Thorac Cardiovasc Surg. 2018 Jun 20;24(3):131-138. doi: 10.5761/atcs.oa.18-00027. Epub 2018 Apr 20.

40.

Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.

Oda N, Miyahara N, Senoo S, Itano J, Taniguchi A, Morichika D, Fujii U, Maeda Y, Kiura K, Kanehiro A.

Allergol Int. 2018 Oct;67(4):521-523. doi: 10.1016/j.alit.2018.03.004. Epub 2018 Apr 14. No abstract available.

41.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.

42.

Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery.

Makimoto G, Kubo T, Oze I, Ohashi K, Hotta K, Tabata M, Soh J, Toyooka S, Katsui K, Takigawa N, Tanimoto M, Kiura K.

Jpn J Clin Oncol. 2018 Mar 1;48(3):287-290. doi: 10.1093/jjco/hyy003.

PMID:
29409038
43.

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.

Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, Ninomiya T, Kubo T, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K.

Sci Rep. 2018 Jan 31;8(1):1955. doi: 10.1038/s41598-018-20326-z.

44.

A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.

Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K.

J Pharm Health Care Sci. 2018 Jan 17;4:2. doi: 10.1186/s40780-018-0098-y. eCollection 2018.

45.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

46.

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K.

Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21.

47.

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.

J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.

48.

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.

Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.

Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.

PMID:
29290249
49.

Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells.

Honda Y, Takigawa N, Ichihara E, Ninomiya T, Kubo T, Ochi N, Yasugi M, Murakami T, Yamane H, Tanimoto M, Kiura K.

Acta Med Okayama. 2017 Dec;71(6):505-512. doi: 10.18926/AMO/55587. No abstract available.

50.

Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

J Thorac Dis. 2017 Sep;9(9):3076-3086. doi: 10.21037/jtd.2017.08.87.

Supplemental Content

Support Center